London-listed Hikma Pharmaceuticals (LSE: HIK) saw its share gain more than 2% to 2,415 pence by late morning, as the company, announces the approval of Kloxxado (naloxone hydrochloride) nasal spray 8mg, by the US Food and Drug Administration for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients.
Kloxxado contains twice as much naloxone per spray as Emergent BioSolutions’ (NYSE: EBS), Narcan Nasal Spray 4mg in a ready-to-use nasal spray to reverse the effects of opioid overdose, providing an important new treatment option in addressing the opioid epidemic, noted Hikma, which was found in Jordan in 1978, and said it expects Kloxxado to become available in the second half of 2021.
Drug overdose, including most commonly opioid overdose, has been described as the "leading cause of accidental death" in the US today - a situation that has been exacerbated by the COVID-19 pandemic.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze